EdiGene Revenue and Competitors

Beijing, China

Location

$179.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • EdiGene's estimated annual revenue is currently $2.2M per year.(i)
  • EdiGene's estimated revenue per employee is $38,750
  • EdiGene's total funding is $179.7M.

Employee Data

  • EdiGene has 57 Employees.(i)
  • EdiGene grew their employee count by -28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.2M131-2%$312.8MN/A
#2
$4.2M54N/AN/AN/A
#3
$2.2M57-28%$179.7MN/A
#4
$28M361-40%N/AN/A
#5
$0.9M12-8%N/AN/A
#6
$1.7M22-15%N/AN/A
#7
$22M2840%N/AN/A
#8
$9.1M11855%N/AN/A
Add Company

EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies.  Founded in 2015, EdiGene is headquartered in Beijing, with subsidiaries in Guangzhou, China and Cambridge, Massachusetts, USA.

keywords:N/A

$179.7M

Total Funding

57

Number of Employees

$2.2M

Revenue (est)

-28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

EdiGene News

2022-04-06 - EdiGene Enters Research Collaboration With Peking ...

By leveraging EdiGene's systematic research on related genes responding to specific targeted therapy for advanced colorectal cancer, and our...

2022-04-06 - EdiGene, Peking University Cancer Hospital Partner on ...

"By leveraging EdiGene's systematic research on related genes responding to specific targeted therapy for advanced colorectal cancer, and our...

2021-04-22 - China’s genome editing startup EdiGene nets $62m in Series B+ round

Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation. The Series B+ round roped in new investors ...

2020-10-14 - Chinese biotech firm EdiGene nabs $67m from Sequoia, IDG, others

Premium Chinese novel gene-editing platform EdiGene Inc has raised 450 million yuan ($67 million) in its Series B round funding led by Chinese healthcare industry focused private equity fund 3H Health, according to a company statement on October 13. Continue reading this story with a subscript ...

2020-10-13 - EdiGene Raises Approx. USD 67M in Series B Financing

EdiGene, Inc., a Beijing, China-based developer of genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, completed an RMB 450 million (approximately USD 67 million) Series B financing. The round was led by 3H Health Investment wit ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.7M572%N/A
#2
$7.6M587%N/A
#3
$192590M61-8%N/A
#4
N/A6340%N/A
#5
$11.6M633%N/A

EdiGene Executives


NameTitle
Wei DongCEO
Si YajunCOO
Yuan PengfeiCTO
Yun LiSVP- Clinical Development
Kehua FanVP- Business Development